SCHEMBL302774

SCHEMBL302774

CN1CCOc2cc(S(=O)(=O)N(Cc3ccccc3)c3cccc(N4CCOCC4)c3)ccc21

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 6/20 0.58
HTR1A P08908 4/20 0.58
HTR2A P28223 4/20 0.58
HTR7 P34969 4/20 0.58
DRD3 P35462 4/20 0.58
HTR6 P50406 4/20 0.58
EP300 Q09472 1/20 0.46
HIF1A Q16665 1/20 0.46
CNR2 P34972 3/20 0.45
RORC P51449 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.44
POLB P06746 1/20 0.44
CNR1 P21554 1/20 0.43
ALDH1A1 P00352 2/20 0.42
HPGD P15428 1/20 0.42
HTT P42858 1/20 0.42
PTGES2 Q9H7Z7 1/20 0.41
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3377040 0.85 LMNA (0.48) HTR2CHTR1AHTR2AHTR7DRD3
SCHEMBL1966251 0.85 HTR2C (0.49) HTR2CHTR1AHTR2AHTR7DRD3
SCHEMBL301830 0.83 HTR2C (0.61) HTR2CHTR1AHTR2AHTR7DRD3
SCHEMBL3378121 0.79 MAPT (0.46) HTR2CHTR1AHTR2AHTR7DRD3
SCHEMBL304739 0.78 CNR2 (0.43) HTR2CHTR1AHTR2AHTR7DRD3
SCHEMBL303069 0.77 HTR2C (0.55) HTR2CHTR1AHTR2AHTR7DRD3
SCHEMBL1966437 0.76 HTR7 (0.69) HTR2CHTR1AHTR2AHTR7DRD3
SCHEMBL3281350 0.75 HTR2C (0.53) HTR2CHTR1AHTR2AHTR7DRD3
SCHEMBL3275347 0.74 HTR2C (0.54) HTR2CHTR1AHTR2AHTR7DRD3
SCHEMBL3377457 0.73 MAPT (0.40) HTR2CHTR1AHTR2AHTR7DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2334637-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-01-04 EP claimed
US-8372840-B2 Potassium channel blockers XENTION LIMITED (GB) 2013-02-12 US claimed
JP-2012500835-A 2012-01-12 JP claimed
EP-2334637-A1 NOVEL POTASSIUM CHANNEL BLOCKERS Xention Limited (GB) 2011-06-22 EP claimed
US-20100087438-A1 New Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US claimed
WO-2010023446-A1 NOVEL POTASSIUM CHANNEL BLOCKERS XENTION LIMITED (GB) 2010-03-04 WO claimed
EP-2334637-B1 NOVEL POTASSIUM CHANNEL BLOCKERS JAPAN TOBACCO INC (JP) 2017-01-04 EP disclosed
US-8372840-B2 Potassium channel blockers XENTION LIMITED (GB) 2013-02-12 US disclosed
US-20100087438-A1 New Potassium Channel Blockers XENTION LIMITED (GB) 2010-04-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087438-A1 New Potassium Channel Blockers KCNJ2, KCNB1, KCNJ11 HTR2C 3430/4885HTR1A 1235/4885HTR2A 2470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.